Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study

Author(s): Inci Kizildag Yirgin*, Gulgun Engin, Şeyma Yildiz, Esra Cureoglu Aydin, Hasan Karanlik, Neslihan Cabioglu, Mustafa Tukenmez, Selman Emiroglu, Semen Onder, Sevda Ozel Yildiz, Ekrem Yavuz, Pınar Saip, Adnan Aydiner, Abdullah Igci and Mahmut Muslumanoglu

Volume 18, Issue 10, 2022

Published on: 22 April, 2022

Article ID: e230222201375 Pages: 9

DOI: 10.2174/1573405618666220223142009

Price: $65

Abstract

Objectives: This study aims to investigate the efficacy of abbreviated breast magnetic resonance imaging (MRI) in neoadjuvant chemotherapy (NAC) response evaluation.

Methods: MR images of 50 locally advanced breast cancer patients who underwent standard protocol (SP) breast MRI before and after NAC were re-evaluated retrospectively. Abbreviated protocol (AP) was obtained by extracting images from SP and then evaluating them in a separate session. Protocols were compared with the histological findings after surgery as the reference standard.

Results: A statistically significant difference was found between the two protocols in response evaluation by the McNemar test (p=0.018). However, the Kappa value was 0.62 (p<0.001), which indicates substantial agreement. No statistically significant differences were found between the two protocols (AP and SP) and pathological results in the McNemar test (p=0.12, p=0.60, respectively). Kappa values were 0.48 (p<0.001) and 0.60 (p<0.001), respectively, which indicates moderate agreement for both protocols with higher values by SP evaluation. The residual maximum median diameters were smaller than the pathology, with both protocols (p<0.001).

Conclusion: Despite the statistical differences, there was a significant correlation in response evaluation between the two protocols. The pathological results were moderately correlated with both protocols, with SP slightly higher. However, the residual maximum median diameters were smaller than the pathology with both protocols. These results may limit the use of AP in evaluating the local extent of the tumor, especially in patients who will undergo breast-conserving surgery.

Keywords: Breast, breast neoplasm, drug therapy, magnetic resonance ımaging, neoadjuvant therapy, radiology.

Graphical Abstract

[1]
Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol 2011; 103(4): 348-57.
[http://dx.doi.org/10.1002/jso.21696] [PMID: 21337570]
[2]
Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26(5): 814-9.
[http://dx.doi.org/10.1200/JCO.2007.15.3510] [PMID: 18258991]
[3]
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30(30): 96-102.
[http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003469] [PMID: 11773300]
[4]
van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary oper-able breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19(22): 4224-37.
[http://dx.doi.org/10.1200/JCO.2001.19.22.4224] [PMID: 11709566]
[5]
Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclo-phosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24(13): 2019-27.
[http://dx.doi.org/10.1200/JCO.2005.04.1665] [PMID: 16606972]
[6]
Mersin H, Yildirim E, Berberoglu U, Gülben K. The prognostic importance of triple negative breast carcinoma. Breast 2008; 17(4): 341-6.
[http://dx.doi.org/10.1016/j.breast.2007.11.031] [PMID: 18450442]
[7]
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemother-apy. J Clin Oncol 2007; 25(28): 4414-22.
[http://dx.doi.org/10.1200/JCO.2007.10.6823] [PMID: 17785706]
[8]
Chaudry M, Lei X, Gonzalez-Angulo AM, et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2015; 153(2): 417-23.
[http://dx.doi.org/10.1007/s10549-015-3533-x] [PMID: 26272743]
[9]
Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute conference. J Clin Oncol 2008; 26(5): 791-7.
[http://dx.doi.org/10.1200/JCO.2007.15.0326] [PMID: 18258988]
[10]
von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31(29): 3623-30.
[http://dx.doi.org/10.1200/JCO.2012.45.0940] [PMID: 24002511]
[11]
Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast can-cer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 2018; 267(5): 946-51.
[http://dx.doi.org/10.1097/SLA.0000000000002313] [PMID: 28549010]
[12]
Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: A meta-analysis. Clin Breast Cancer 2017; 17(4): 245-55.
[http://dx.doi.org/10.1016/j.clbc.2016.12.010] [PMID: 28209330]
[13]
Liu Q, Wang C, Li P, Liu J, Huang G, Song S. The role of (18)F-FDG PET/CT and MRI in assessing pathological complete response to neo-adjuvant chemotherapy in patients with breast cancer: A systematic review and meta-analysis. BioMed Res Int 2016; 2016: 3746232.
[http://dx.doi.org/10.1155/2016/1235429] [PMID: 26981529]
[14]
Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): First postcon-trast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 2014; 32(22): 2304-10.
[http://dx.doi.org/10.1200/JCO.2013.52.5386] [PMID: 24958821]
[15]
Kuhl CK. Abbreviated magnetic resonance imaging (MRI) for breast cancer screening: rationale, concept, and transfer to clinical practice. Annu Rev Med 2019; 70: 501-19.
[http://dx.doi.org/10.1146/annurev-med-121417-100403] [PMID: 30691370]
[16]
Mango VL, Morris EA, David Dershaw D, et al. Abbreviated protocol for breast MRI: Are multiple sequences needed for cancer detection? Eur J Radiol 2015; 84(1): 65-70.
[http://dx.doi.org/10.1016/j.ejrad.2014.10.004] [PMID: 25454099]
[17]
Heacock L, Melsaether AN, Heller SL, et al. Evaluation of a known breast cancer using an abbreviated breast MRI protocol: Correlation of imaging characteristics and pathology with lesion detection and conspicuity. Eur J Radiol 2016; 85(4): 815-23.
[http://dx.doi.org/10.1016/j.ejrad.2016.01.005] [PMID: 26971429]
[18]
Grimm LJ, Soo MS, Yoon S, Kim C, Ghate SV, Johnson KS. Abbreviated screening protocol for breast MRI: a feasibility study. Acad Radiol 2015; 22(9): 1157-62.
[http://dx.doi.org/10.1016/j.acra.2015.06.004] [PMID: 26152500]
[19]
Harvey SC, Di Carlo PA, Lee B, Obadina E, Sippo D, Mullen L. An abbreviated protocol for high risk screening breast MRI saves time and resources. J Am Coll Radiol 2016; 13(4): 374-80.
[http://dx.doi.org/10.1016/j.jacr.2015.08.015] [PMID: 26521970]
[20]
Dogan BE, Scoggins ME, Son JB, et al. American college of radiology-compliant short protocol breast MRI for high-risk breast cancer screening: A prospective feasibility study. AJR Am J Roentgenol 2018; 210(1): 214-21.
[http://dx.doi.org/10.2214/AJR.17.18267] [PMID: 29091003]
[21]
Choi BH, Choi N, Kim MY, Yang J-HJ-H, Yoo YB, Jung HK. Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery. Breast Cancer Res Treat 2018; 167(2): 495-502.
[http://dx.doi.org/10.1007/s10549-017-4530-z] [PMID: 29030785]
[22]
Park KW, Han SB, Han B-KK, et al. MRI surveillance for women with a personal history of breast cancer: Comparison between abbreviated and full diagnostic protocol. Br J Radiol 2020; 93(1106): 20190733.
[http://dx.doi.org/10.1259/bjr.20190733] [PMID: 31868524]
[23]
Lee-Felker S, Joines M, Storer L, et al. Abbreviated breast MRI for estimating extent of disease in newly diagnosed breast cancer. J Breast Imaging 2020; 2(1): 43-9.
[http://dx.doi.org/10.1093/jbi/wbz071]
[24]
Shiraishi M, Igarashi T, Terayama T, Watanabe K, Ashida H, Ojiri H. Breast magnetic resonance imaging for estimation of the tumour extent in patients with pure ductal carcinoma in situ: Comparison between full diagnostic and abbreviated protocols. Eur J Radiol 2020; 123: 108788.
[http://dx.doi.org/10.1016/j.ejrad.2019.108788] [PMID: 31874302]
[25]
Girometti R, Nitti A, Lorenzon M, Greco F, Londero V, Zuiani C. Comparison between an abbreviated and full MRI protocol for detecting additional disease when doing breast cancer staging. J Magn Reson Imaging 2019; 49(7): e222-30.
[http://dx.doi.org/10.1002/jmri.26339] [PMID: 30350391]
[26]
Kim ES, Cho N, Kim SY, et al. Comparison of abbreviated MRI and full diagnostic MRI in distinguishing between benign and malignant lesions detected by breast MRI: A multireader study. Korean J Radiol 2021; 22(3): 297-307.
[http://dx.doi.org/10.3348/kjr.2020.0311] [PMID: 33289355]
[27]
American College of Radiology. Breast Magnetic Resonance Imaging (MRI) Accreditation Program Requirements. 2017. Available from: https://www.acraccreditation.org//media/ACRAccreditation/Documents/BreastMRI/Requirements.pdf (Accessed June 6, 2019).
[28]
Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clini-cal practice. Radiology 2007; 244(2): 356-78.
[http://dx.doi.org/10.1148/radiol.2442051620] [PMID: 17641361]
[29]
Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008; 18(7): 1307-18.
[http://dx.doi.org/10.1007/s00330-008-0863-7] [PMID: 18389253]
[30]
Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci 2018; 3(6): 861-70.
[http://dx.doi.org/10.1016/j.jacbts.2018.06.005] [PMID: 30623145]
[31]
Kim TH, Kang DK, Yim H, Jung YS, Kim KS, Kang SY. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemo-therapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. J Comput Assist Tomogr 2012; 36(2): 200-6.
[http://dx.doi.org/10.1097/RCT.0b013e318246abf3] [PMID: 22446360]
[32]
Ko ES, Morris EA. Abbreviated magnetic resonance imaging for breast cancer screening: Concept, early results, and considerations. Korean J Radiol 2019; 20(4): 533-41.
[http://dx.doi.org/10.3348/kjr.2018.0722] [PMID: 30887736]
[33]
Hernández ML, Osorio S, Florez K, Ospino A, Díaz GM. Abbreviated magnetic resonance imaging in breast cancer: A systematic review of literature. Eur J Radiol Open 2020; 8: 100307.
[http://dx.doi.org/10.1016/j.ejro.2020.100307] [PMID: 33364260]
[34]
Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: Comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14(8): 1371-9.
[http://dx.doi.org/10.1007/s00330-004-2246-z] [PMID: 14986052]
[35]
Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003; 181(5): 1275-82.
[http://dx.doi.org/10.2214/ajr.181.5.1811275] [PMID: 14573420]
[36]
Weber JJ, Jochelson MS, Eaton A, et al. MRI and prediction of pathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer. J Am Coll Surg 2017; 225(6): 740-6.
[http://dx.doi.org/10.1016/j.jamcollsurg.2017.08.027] [PMID: 28919579]
[37]
Sener SF, Sargent RE, Lee C, et al. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. J Surg Oncol 2019; 120(6): 903-10.
[http://dx.doi.org/10.1002/jso.25663] [PMID: 31400007]
[38]
Negrão EMS, Souza JA, Marques EF, Bitencourt AGV. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol 2019; 120: 108701.
[http://dx.doi.org/10.1016/j.ejrad.2019.108701] [PMID: 31610321]
[39]
Gampenrieder SP, Peer A, Weismann C, et al. Radiologic Complete Response (rCR) in Contrast-Enhanced Magnetic Resonance Imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic Complete Response (pCR). Breast Cancer Res 2019; 21(1): 19.
[http://dx.doi.org/10.1186/s13058-018-1091-y] [PMID: 30704493]
[40]
Hieken TJ, Boughey JC, Jones KN, Shah SS, Glazebrook KN. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol 2013; 20(10): 3199-204.
[http://dx.doi.org/10.1245/s10434-013-3118-z] [PMID: 23846781]
[41]
You S, Kang DK, Jung YS, An YS, Jeon GS, Kim TH. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: Comparison of diagnostic performance of ultrasound, MRI and 18F-FDG PET/CT. Br J Radiol 2015; 88(1052): 20150143.
[http://dx.doi.org/10.1259/bjr.20150143] [PMID: 26110204]
[42]
Schipper RJ, Moossdorff M, Beets-Tan RGH, Smidt ML, Lobbes MBI. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review. Eur J Radiol 2015; 84(1): 41-7.
[http://dx.doi.org/10.1016/j.ejrad.2014.09.020] [PMID: 25458227]
[43]
Ha SM, Cha JH, Kim HH, Shin HJ, Chae EY, Choi WJ. Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer. Acta Radiol 2017; 58(10): 1198-205.
[http://dx.doi.org/10.1177/0284185117690421] [PMID: 28350255]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy